Page last updated: 2024-11-05

trazodone and Anterior Horn Cell Disease

trazodone has been researched along with Anterior Horn Cell Disease in 1 studies

Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Wong, C1
Dakin, RS1
Williamson, J1
Newton, J1
Steven, M1
Colville, S1
Stavrou, M1
Gregory, JM1
Elliott, E1
Mehta, AR1
Chataway, J1
Swingler, RJ1
Parker, RA1
Weir, CJ1
Stallard, N1
Parmar, MKB1
Macleod, MR1
Pal, S1
Chandran, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial[NCT04302870]Phase 2/Phase 3800 participants (Anticipated)Interventional2020-02-27Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for trazodone and Anterior Horn Cell Disease

ArticleYear
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
    BMJ open, 2022, 07-07, Volume: 12, Issue:7

    Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Memantine; Motor Neuron Disease; Neurode

2022